Bifidobacterium Market Size - By Product Type (Bifidobacterium Longum, Bifidobacterium Breve, Bifidobacterium Infantis, Bifidobacterium Animalis, Bifidobacterium Lactis), Application, End Use, Distribution Channel & Global Forecast, 2023

List of Tables

Bifidobacterium Market size is poised to 8% CAGR from 2023 to 2032, propelled by continuous research for numerous health benefits.

Several scientific studies have revealed the positive impacts of bifidobacterium on gut health, immune function, and overall well-being. As a result, consumers are increasingly seeking products containing bifidobacterium to address digestive issues, boost immunity, and support health proactively. The growing body of research is not only fostering consumer confidence but also encouraging innovations and the development of new formulations for expanding the availability and application of bifidobacterium-based products.

The bifidobacterium market is categorized based on product type, application, end use, distribution channel, and region.

With respect to product type, the market size from the bifidobacterium animalis segment is projected to gain significant traction through 2032. The growth can be attributed to the rising importance of bifidobacterium animalis as probiotic strains for their potential health benefits, particularly in supporting digestive health and immunity. A study published in June 2022 found that supplementing with Bifidobacterium animalis subsp. lactis (Bifal) and arginine (Arg) could significantly boost human cognition, particularly in older adults. To that end, consumers are increasingly seeking products containing bifidobacterium animalis to improve gut microbiome and overall well-being.

Based on application, the bifidobacterium industry from the pharmaceutical segment will record robust growth from 2023-2032. Bifidobacterium strains are increasingly utilized in pharmaceutical products, particularly in probiotic supplements and medications for addressing various health conditions. Lately, pharmaceutical companies are incorporating beneficial probiotics into formulations due to their potential to enhance overall health and well-being. The surging number of probiotic R&D investments in the pharmaceutical industry along with the growing demand for probiotic-based pharmaceutical solutions will add to the segment growth.

Regional, the bifidobacterium market in Europe will witness considerable growth up to 2032 due to the strong emphasis on health and wellness along with the growing awareness of the importance of gut health and the role of probiotics. There has been higher consumer demand for probiotic products, including dairy, supplements, and functional foods containing Bifidobacterium strains in the region. Additionally, favorable regulatory frameworks and guidelines will support the market growth.

Product Code: 6218

Chapter 1 Methodology & Scope

1.1 Industry coverage
1.2 Market scope & definition
1.3 Base estimates & calculations
- 1.3.1 Data collection
1.4 Forecast parameters
1.5 COVID-19 impact analysis at the global level
1.6 Data validation
1.7 Data sources
- 1.7.1 Primary
- 1.7.2 Secondary
  - 1.7.2.1 Paid sources
  - 1.7.2.2 Unpaid sources

Chapter 2 Executive Summary

2.1 Bifidobacterium industry 360 degree synopsis, 2018 - 2032
2.2 Business trends
2.3 Product trends
2.4 Application trends
2.5 End-use trends
2.6 Distribution channel trends
2.7 Regional trends

Chapter 3 Bifidobacterium Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Rising demand for probiotic products
  - 3.2.1.2 Growing interest in personalized nutrition
  - 3.2.1.3 Innovations in delivery formats
- 3.2.2 Industry pitfalls & challenges
  - 3.2.2.1 Regulatory challenges
  - 3.2.2.2 Shelf stability & viability
  - 3.2.2.3 Product formulation & compatibility
3.3 Growth potential analysis
- 3.3.1 By product
- 3.3.2 By application
- 3.3.3 By end use
- 3.3.4 By distribution channel
3.4 COVID-19 impact analysis
3.5 Impact of Russia Ukraine war
3.6 Regulatory landscape
- 3.6.1 U.S.
- 3.6.2 Europe
3.7 Pricing analysis, 2022
3.8 Reimbursement scenario
3.9 Technology landscape
3.10 Future market trends
3.11 Porter's analysis
3.12 PESTEL analysis

Chapter 4 Competitive Landscape, 2022

4.1 Introduction
4.2 Company matrix analysis, 2022
4.3 Global company market share analysis, 2022
4.4 Competitive positioning matrix
4.5 Strategy dashboard

Chapter 5 Bifidobacterium Market Size and Forecast, By Product 2018 - 2032

5.1 Key trends, by product
5.2 Bifidobacterium longum
5.3 Bifidobacterium breve
5.4 Bifidobacterium infantis
5.5 Bifidobacterium animalis
5.6 Bifidobacterium lactis
5.7 Other Bifidobacterium strains

Chapter 6 Bifidobacterium Market Size and Forecast, By Application 2018 - 2032

6.1 Key trends, by application
6.2 Dietary Supplements
6.3 Functional Foods and Beverages
6.4 Animal Feed
6.5 Pharmaceuticals
6.6 Others

Chapter 7 Bifidobacterium Market Size and Forecast, By End Use 2018 - 2032

7.1 Key trends, by end use
7.2 Adults
7.3 Children
7.4 Infants
7.5 Animals

Chapter 8 Bifidobacterium Market Size and Forecast, By Distribution Channel 2018 - 2032

8.1 Key trends, by distribution channel
8.2 Online retail
8.3 Supermarkets
8.4 Health Stores
8.5 Pharmacies
8.6 Others

Chapter 9 Bifidobacterium Market Size and Forecast, By Region 2018 - 2032

9.1 Key trends, by region
9.2 North America
- 9.2.1 U.S.
- 9.2.2 Canada
9.3 Europe
- 9.3.1 Germany
- 9.3.2 UK
- 9.3.3 France
- 9.3.4 Spain
- 9.3.5 Italy
9.4 Asia Pacific
- 9.4.1 Japan
- 9.4.2 China
- 9.4.3 India
- 9.4.4 Australia
- 9.4.5 South Korea
- 9.4.6 Indonesia
- 9.4.7 Malaysia
9.5 Latin America
- 9.5.1 Brazil
- 9.5.2 Mexico
- 9.5.3 Argentina
9.6 MEA
- 9.6.1 South Africa
- 9.6.2 Saudi Arabia
- 9.6.3 UAE
- 9.6.4 Egypt

Chapter 10 Company Profiles

10.1 DuPont de Nemours, Inc.
10.2 Chr. Hansen Holding A/S
10.3 Lallemand Inc.
10.4 Kerry Group
10.5 Probi AB
10.6 Morinaga Milk Industry Co., Ltd.
10.7 Yakult Honsha Co., Ltd.
10.8 Nestlé S.A.
10.9 Danone S.A.
10.10 Bifodan A/S
10.11 Ganeden Biotech
10.12 BioGaia AB
10.13 Sabinsa Corporation
10.14 Lallemand Inc.
10.15 Biocare Copenhagen A/S